Blood test for Alzheimer’s is coming, scientists report

A test that measures beta amyloid protein in the blood is more accurate than a brain scan and may indicate trouble years earlier

Structure of the amyloid beta peptide   bound to the cell membrane. Scientists at Washington University  reported that they had devised the most sensitive blood test yet. Photograph: Getty Images/iStockphoto

Structure of the amyloid beta peptide bound to the cell membrane. Scientists at Washington University reported that they had devised the most sensitive blood test yet. Photograph: Getty Images/iStockphoto

 

For decades, researchers have sought a blood test for beta amyloid, the protein that is a hallmark of Alzheimer’s disease. Several groups and companies have made progress, and this month, scientists at Washington University in St Louis reported that they had devised the most sensitive blood test yet.

The test will not be available for clinical use for years, and in any event, amyloid is not a perfect predictor of Alzheimer’s disease: most symptomless older people with amyloid deposits in their brains will not develop dementia.

But the protein is a significant risk factor, and the new blood test identified patients with amyloid deposits before brain scans did. That will be important to scientists conducting trials of drugs to prevent Alzheimer’s. They need to find participants in the earliest stages of the disease.

At present, a diagnosis of Alzheimer’s disease is not easy to make. Doctors rely mostly on tests of mental acuity and interviews with the patient and family members. Studies have shown that community doctors are only 50 per cent to 60 per cent accurate in diagnosing the condition – about the same as tossing a coin.

Methods that can improve accuracy, like PET scans of the brain, are expensive and often not available.

Technical advances

The new test relies on mass spectrometry, a tool used in analytical chemistry that, with recent technical advances, can find elusive beta amyloid molecules in blood with high precision. The lead investigator, Dr Randall Bateman, a neurologist at Washington University, has been working on a mass spectrometry test for 20 years. He and a colleague, Dr David Holtzman, founded a company 10 years ago and licensed patents from their university to commercialise a mass spectrometry test if they ever developed one.

Amyloid is a normal brain protein, formed from the breakdown of a much bigger protein. No one knows what its function is. “We don’t know if it has a function,” said Dr Suzanne Schindler, a neurologist and first author of the new paper. “It might just be a piece of trash.”

The idea behind the blood test is somewhat paradoxical: if blood amyloid levels are very low, the patient may well have plaques in the brain. The reason, Schindler said, is that amyloid is “sticky”. As it gets trapped in clumps in the brain, levels dip in the blood.

The new study involved 158 volunteers mostly in their 60s and 70s. Most were cognitively normal. They came periodically for tests of memory and reasoning and received spinal taps and brain scans.

Schindler and her colleagues used mass spectrometry to test the volunteers’ stored blood for beta amyloid. Then they asked if the beta amyloid levels predicted the results of PET scans that the participants received over the years.

Treatment

Mass spectrometry identified asymptomatic people as accumulating beta amyloid in their brains when PET scans were still negative, the researchers found. The scans only turned up beta amyloid in the brain years later.

The researchers combined the blood test results with other factors known to influence the risk of Alzheimer’s disease – age, and the presence or absence of a gene variant, ApoE4 – and found the blood test was 94 per cent accurate in predicting the presence of plaques even in mostly asymptomatic people.

There is no treatment for Alzheimer’s, and very early diagnosis of any disease can be problematic, since it may not progress. So the first use for this blood test will probably be to screen people for clinical trials of drugs to prevent Alzheimer’s disease, said Dr Michael Weiner, a neurologist at the University of California, San Francisco. “If you are doing a prevention trial, you are looking for evidence of the disease that is silent,” he said.

About a quarter of people in their mid-70s are starting to accumulate amyloid in plaques in their brains, but their memories and reasoning abilities are intact. To identify patients for prevention trials, researchers have to perform a lot of PET scans at a big cost, Weiner said. A simple blood test would cost much less. “It’s fantastic,” he said.

– New York Times

The Irish Times Logo
Commenting on The Irish Times has changed. To comment you must now be an Irish Times subscriber.
SUBSCRIBE
GO BACK
Error Image
The account details entered are not currently associated with an Irish Times subscription. Please subscribe to sign in to comment.
Comment Sign In

Forgot password?
The Irish Times Logo
Thank you
You should receive instructions for resetting your password. When you have reset your password, you can Sign In.
The Irish Times Logo
Please choose a screen name. This name will appear beside any comments you post. Your screen name should follow the standards set out in our community standards.
Screen Name Selection

Hello

Please choose a screen name. This name will appear beside any comments you post. Your screen name should follow the standards set out in our community standards.

The Irish Times Logo
Commenting on The Irish Times has changed. To comment you must now be an Irish Times subscriber.
SUBSCRIBE
Forgot Password
Please enter your email address so we can send you a link to reset your password.

Sign In

Your Comments
We reserve the right to remove any content at any time from this Community, including without limitation if it violates the Community Standards. We ask that you report content that you in good faith believe violates the above rules by clicking the Flag link next to the offending comment or by filling out this form. New comments are only accepted for 3 days from the date of publication.